Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay.

Annals of neurology - 1 Jul 2005

Stenh Charlotte, Englund Hillevi, Lord Anna, Johansson Ann-Sofi, Almeida Claudia G, Gellerfors Pär, Greengard Paul, Gouras Gunnar K, Lannfelt Lars, Nilsson Lars N G

Abstract excerpt

Amyloid-beta (Abeta) peptide levels are widely measured by enzyme-linked immunosorbent assay (ELISA) in Alzheimer's disease research. Here, we show that oligomerization of Abeta results in underestimated Abeta ELISA levels. The implications are that comprehensive analysis of soluble Abeta requires either sample pretreatment at denaturing conditions or novel conformation-dependent immunoassays. Our findings might...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease
Share to Amyloid beta-Peptides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Blotting, Western

Share to Cell Line

Share to Enzyme-Linked Immunosorbent Assay

Share to Mice, Transgenic

Share to Transfection

Source

Identifiers

PMID: 15984012
DOI: 10.1002/ana.20524

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay.PMID 15984012Read ↗

Soluble Aβ oligomer production and toxicitySemantic proximity Read ↗

Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease.Semantic proximity Read ↗

Amyloid β-protein oligomers and Alzheimer’s diseaseSemantic proximity Read ↗

Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease.Semantic proximity Read ↗

A Specific Enzyme-Linked Immunosorbent Assay for Measuring β-Amyloid Protein Oligomers in Human Plasma and Brain Tissue of Patients With Alzheimer DiseaseSemantic proximity Read ↗

Oligomeric amyloid beta-protein as a therapeutic target in Alzheimer's disease: its significance based on its distinct localization and the occurrence of a familial variant form.Semantic proximity Read ↗

The aqueous phase of Alzheimer's disease brain contains assemblies built from ∼4 and ∼7 kDa Aβ speciesSemantic proximity Read ↗

New plasma LC-MS/MS assays for the quantitation of beta-amyloid peptides and identification of apolipoprotein E proteoforms for Alzheimer’s disease risk assessmentSemantic proximity Read ↗

Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (Abeta) assembly from Alzheimer disease brains.Semantic proximity Read ↗

Multimer Detection System: A Universal Assay System for Differentiating Aggregated Proteins/Oligomers from MonomersSemantic proximity Read ↗

On-line high-performance liquid chromatography/mass spectrometric investigation of amyloid-beta peptide variants found in Alzheimer's disease.Semantic proximity Read ↗

Potential amyloid plaque-specific peptides for the diagnosis of Alzheimer's diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.